Barclays Downgrades Sarepta Therapeutics (SRPT) to Equalweight
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/29/2026
- Stocks fall as higher oil prices, Treasury yields weigh
- S&P 500 breadth hits lowest level since dot-com bubble, Goldman says
- Nvidia’s AI dominance funds historic $150 billion buyback
- MongoDB stock drops 15% as CEO Desai resigns for Meta
- Jefferies cuts Roblox to Underperform, says rally is too optimistic
Citi Opens 90d Downside Catalyst Watch on Sarepta Therapeutics (SRPT)
July 24, 2025 6:46 AM EDTCiti Opens 90d Downside Catalyst Watch on Sarepta Therapeutics (NASDAQ: SRPT)
The analyst comments "We are opening a 90-day downside short-term view on SRPT. Our view is anchored on new and open questions surrounding Elevidys marketing approval in ambulatory Duchenne patients, the possibility of... More
